REUN Share Price Performance

REUN Community Fair Values

View all narratives

Recent REUN News & Updates

No updates

Reunion Neuroscience Inc. Key Details

Last Reported Earnings

Mar 31, 2023

Next Reporting Earnings

n/a

Earnings per share (EPS): -3.25
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: 0%

View full report ›

Reunion Neuroscience Inc. Competitors

About REUN

Founded: 2008
Employees: 16
CEO: Gregory Mayes
WebsiteView website: reunionneuro.com

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Canadian Market Performance

0.6%

19.7%

19.3%

8.5%

Over the last 7 days, the market has remained flat, although notably the Communication Services sector gained 4.6% in that time. As for the longer term, the market has risen 19% in the past 12 months. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

Reunion Neuroscience Stock Price

REUN Share Price Performance

REUN Community Fair Values

Recent REUN News & Updates

Reunion Neuroscience Inc. Key Details

Reunion Neuroscience Inc. Competitors

AAJ Capital 3

China Keli Electric

St. Davids Capital

Oa Capital

Victory Opportunities 1

Zoglo's Food

Little Fish Acquisition I

Castlecap Capital

🎢 From Panic to Peak: Q2’s Wild Ride and What’s Next

🏛️ The Winners and Losers From The Stablecoin GENIUS Act